Betapace

Betapace is the brand name for sotalol, a medication that combines non-selective beta-adrenergic blocking with class III antiarrhythmic properties. It reduces heart rate through beta-blockade and prolongs the cardiac action potential by blocking potassium channels, which can help restore and maintain normal heart rhythm in certain arrhythmias.

Indications and uses include the treatment of certain ventricular arrhythmias and the maintenance of sinus rhythm in adults with atrial fibrillation or flutter after conversion to a normal rhythm. Betapace AF refers to a formulation of sotalol designed for atrial fibrillation/flutter. The drug is prescribed by clinicians with expertise in rhythm disorders and is typically initiated in a hospital setting due to the risk of serious heart rhythm changes.

Administration and monitoring: Betapace is available in oral and injectable forms. Initiation or dose changes require careful ECG monitoring, electrolyte assessment, and renal function testing because of the risk of QT interval prolongation and torsades de pointes, a potentially life-threatening ventricular tachycardia. Dose adjustments are often necessary in patients with reduced kidney function, and concurrent use with other QT-prolonging drugs or drugs that affect heart rate requires caution.

Contraindications and precautions include significant bradycardia, second- or third-degree AV block, sinus node dysfunction without a pacemaker, decompensated heart failure, severe hypotension, and bronchospastic diseases such as asthma. Caution is advised in patients with electrolyte disturbances, renal impairment, or a history of torsades de pointes. Use in pregnancy and lactation should be discussed with a clinician.

Adverse effects commonly associated with Betapace include bradycardia, fatigue, dizziness, shortness of breath, hypotension, and potential QT prolongation. Serious arrhythmias and bronchospasm are possible, underscoring the need for careful monitoring and appropriate patient selection.